Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464507 | 0.60 | AHR (0.64) | AHRHSD11B1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL29624840 | 0.60 | AHR (0.64) | AHRHSD11B1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL11423973 | 0.59 | AHR (0.57) | AHRHSD11B1ALDH1A1RAB9AHPGD | |
| SCHEMBL2933108 | 0.57 | AHR (0.67) | AHRHSD11B1KDM4EALDH1A1RAB9A | |
| SCHEMBL4450464 | 0.56 | AHR (0.71) | AHRHSD11B1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL4452962 | 0.55 | AHR (0.56) | AHRHSD11B1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL4454517 | 0.55 | AHR (0.56) | AHRHSD11B1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL29788257 | 0.55 | AHR (0.61) | AHRHSD11B1ALDH1A1RAB9AHPGD | |
| SCHEMBL2908267 | 0.55 | AHR (1.00) | AHRHSD11B1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL510771 | 0.55 | AHR (0.61) | AHRHSD11B1ALDH1A1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | AHR 1228/4885HSD11B1 3089/4885HSP90AA1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.